LIBTAYO study results
LIBTAYO helped shrink tumors in some clinical trial patients.
In 1 clinical trial of 137 patients with CSCC that had spread or could not be cured by surgery or
radiation treated with LIBTAYO*:
63 out of 137 patients (46%)
saw an improvement in their advanced CSCC with LIBTAYO
Actual LIBTAYO patient.
-
In 50 out of 63 patients (79%) who responded to LIBTAYO, the response lasted 6 months or longer
-
In 34 out of 63 patients (54%) who responded to LIBTAYO, the response lasted 12 months or
longer
In the same clinical trial, in a separate group of 56 patients with CSCC that had spread who took LIBTAYO at the recommended dose†:
-
23 out of 56 patients (41%) saw an improvement in their advanced CSCC
- 20 out of 56 patients (36%) saw tumors shrink (partial response)
- 3 out of 56 patients (5%) saw tumors disappear completely (complete response)
-
In 15 out of 23 patients (65%) who responded to LIBTAYO, the response lasted 6 months
or
longer
In a different clinical trial of 26 patients with CSCC that had spread or could not be cured by surgery or radiation*:
-
13 out of 26 patients (50%) saw tumors shrink (all partial responses)
-
In 11 out of 13 patients (85%) who responded to LIBTAYO, the response lasted 6 months
or longer
In these trials, responses lasted between 1 month and more than 2 years (24.2+ months); plus sign (+) means the patient was still responding to treatment at their last assessment.
LIBTAYO may not work for everyone.